Weekly Digests



RIGging the game: LRIG1 induces CD8+ T cell quiescence by engaging VISTA

May 29, 2024

Immune checkpoint inhibitors have revolutionized the cancer immunotherapy field, and V domain immunoglobulin suppressor of T cell activation (VISTA) has garnered attention as a potentially relevant immune regulatory molecule. In preclinical models, VISTA blockade has promoted CD8+ T cell infiltration and inflammatory cytokine secretion in tumors, leading to antitumor efficacy. VISTA appears to...

A glucocorticoid game changer for B cell cancers

May 22, 2024

Glucocorticoids are used in combination with chemotherapy and rituximab for the treatment of B cell malignancies, such as diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and acute lymphoblastic leukemia (ALL). They function as glucocorticoid receptor (GR) agonists to act on downstream signaling related to cell cycle progression and...

TMEs show night and day differences in accordance with circadian rhythms

May 15, 2024

Circadian rhythms allow organisms to operate on 24-hour cycles and coordinate periods of activity and rest in response to light and dark. These oscillations, controlled by both internal and external “clocks”, have also been shown to impact various aspects of the immune system, including responses to vaccines and tumor immune infiltration. To extend...

PGE(2) sabotages TIL expansion and effector differentiation

May 8, 2024

The bioactive lipid prostaglandin E2 (PGE2) is often detected in the tumor microenvironment (TME), and has been shown to play a role in immune escape and cancer progression. Two recent studies published in Nature assessed the effects of PGE2 on tumor-infiltrating lymphocytes (TIL). Lacher, Dörr, et al. investigated its impact on TCF1+CD8+ T...

Targeting IL-2 to CD8+ T cells enhances its benefits while reducing its risks

May 1, 2024

IL-2 is one of the earliest immunotherapeutic agents to induce complete responses in patients with cancer, but its use has been limited by its toxicity and the need for frequent administration. In order to capitalize on the desirable effects of IL-2 while limiting its risks, Moynihan et al. set out to investigate ways...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.